{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:35:16Z","timestamp":1793968516600,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00280-014-2640-4","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:46:27Z","timestamp":1417445187000},"page":"247-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum"],"prefix":"10.1007","volume":"75","author":[{"given":"Ji Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"issue":"2","key":"2640_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69\u201390. doi: 10.3322\/caac.20107","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"2640_CR2","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068\u20133077","journal-title":"J Clin Oncol"},{"issue":"1","key":"2640_CR3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50\u201354. doi: 10.1016\/j.ejca.2005.08.032","journal-title":"Eur J Cancer"},{"issue":"11","key":"2640_CR4","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","volume":"12","author":"BJ Roth","year":"1994","unstructured":"Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12(11):2264\u20132270","journal-title":"J Clin Oncol"},{"key":"2640_CR5","unstructured":"Bajorin DF (2000) Paclitaxel in the treatment of advanced urothelial cancer. Oncology (Williston Park) 14(1):43\u201352, 57; discussion 58, 61\u201342"},{"issue":"8 Suppl","key":"2640_CR6","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.11280","volume":"97","author":"D Raghavn","year":"2003","unstructured":"Raghavn D (2003) Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 97(8 Suppl):2050\u20132055. doi: 10.1002\/cncr.11280","journal-title":"Cancer"},{"issue":"5","key":"2640_CR7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.2000.18.5.1058","volume":"18","author":"R Dreicer","year":"2000","unstructured":"Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G (2000) Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J Clin Oncol 18(5):1058\u20131061","journal-title":"J Clin Oncol"},{"issue":"10","key":"2640_CR8","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.1998.16.10.3392","volume":"16","author":"L Sengel\u00f8v","year":"1998","unstructured":"Sengel\u00f8v L, Kamby C, Lund B, Engelholm SA (1998) Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16(10):3392\u20133397","journal-title":"J Clin Oncol"},{"issue":"2","key":"2640_CR9","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3816\/CGC.2009.n.018","volume":"7","author":"F Joly","year":"2009","unstructured":"Joly F, Hou\u00e9d\u00e9 N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Fl\u00e9chon A, Henry-Amar M, Culine S (2009) Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 7(2):E28\u2013E33","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2640_CR10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/bjc.1997.106","volume":"75","author":"D Papamichael","year":"1997","unstructured":"Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J (1997) Phase II study of paclitaxel in pretreated patients with locally advanced\/metastatic cancer of the bladder and ureter. Br J Cancer 75(4):606\u2013607","journal-title":"Br J Cancer"},{"issue":"4","key":"2640_CR11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.20.4.937","volume":"20","author":"DJ Vaughn","year":"2002","unstructured":"Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(4):937\u2013940","journal-title":"J Clin Oncol"},{"issue":"5","key":"2640_CR12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","volume":"15","author":"JA McCaffrey","year":"1997","unstructured":"McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853\u20131857","journal-title":"J Clin Oncol"},{"issue":"5","key":"2640_CR13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s10637-011-9757-7","volume":"30","author":"JL Lee","year":"2012","unstructured":"Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H (2012) Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 30(5):1984\u20131990. doi: 10.1007\/s10637-011-9757-7","journal-title":"Invest New Drugs"},{"issue":"8","key":"2640_CR14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1470-2045(13)70162-1","volume":"14","author":"Y-J Ko","year":"2013","unstructured":"Ko Y-J, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS (2013) Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 14(8):769\u2013776. doi: 10.1016\/S1470-2045(13)70162-1","journal-title":"Lancet Oncol"},{"issue":"6","key":"2640_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423\u2013436","journal-title":"Nat Rev Cancer"},{"key":"2640_CR16","doi-asserted-by":"crossref","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, De Braud F, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13 (1):73\u201380","DOI":"10.1093\/annonc\/mdf013"},{"issue":"5","key":"2640_CR17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","volume":"64","author":"Y Hamano","year":"2004","unstructured":"Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64(5):1570\u20131574","journal-title":"Cancer Res"},{"issue":"5","key":"2640_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig P, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56(5):641\u2013648. doi: 10.1007\/s00262-006-0225-8","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2640_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cncr.24055","volume":"115","author":"G Lorenzo Di","year":"2009","unstructured":"Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S (2009) Phase 1\/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. Cancer 115(3):517\u2013523. doi: 10.1002\/cncr.24055","journal-title":"Cancer"},{"issue":"18","key":"2640_CR20","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1002\/cncr.24460","volume":"115","author":"DJ Vaughn","year":"2009","unstructured":"Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C (2009) Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115(18):4110\u20134117. doi: 10.1002\/cncr.24460","journal-title":"Cancer"},{"issue":"5","key":"2640_CR21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00000421-199710000-00018","volume":"20","author":"P Pronzato","year":"1997","unstructured":"Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F (1997) Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20(5):519\u2013521","journal-title":"Am J Clin Oncol"},{"issue":"27","key":"2640_CR22","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454\u20134461. doi: 10.1200\/JCO.2008.20.5534","journal-title":"J Clin Oncol"},{"issue":"2","key":"2640_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1997.15.2.589","volume":"15","author":"RS Witte","year":"1997","unstructured":"Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ (1997) Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15(2):589\u2013593","journal-title":"J Clin Oncol"},{"issue":"1","key":"2640_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","volume":"42","author":"S Mielke","year":"2006","unstructured":"Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42(1):24\u201330. doi: 10.1016\/j.ejca.2005.06.030","journal-title":"Eur J Cancer"},{"issue":"4","key":"2640_CR25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.urolonc.2008.03.017","volume":"27","author":"G Sonpavde","year":"2009","unstructured":"Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27(4):391\u2013399. doi: 10.1016\/j.urolonc.2008.03.017","journal-title":"Urol Oncol"},{"issue":"12","key":"2640_CR26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2010.31.6067","volume":"29","author":"NM Hahn","year":"2011","unstructured":"Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 29(12):1525\u20131530. doi: 10.1200\/JCO.2010.31.6067","journal-title":"J Clin Oncol"},{"key":"2640_CR27","unstructured":"Srinivas S, Narayanan S, Harshman L, Lam A, Haas D, Poushnejad S, Pachynski R, Fan A, Vaishampayan U (2014) Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. J Clin Oncol 32(4s): abstr 299"},{"issue":"1","key":"2640_CR28","doi-asserted-by":"crossref","first-page":"35.e21","DOI":"10.1016\/j.urolonc.2013.02.010","volume":"32","author":"D Lamm","year":"2014","unstructured":"Lamm D, Brausi M, O\u2019Donnell MA, Witjes JA (2014) Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 32(1):35.e21\u201335.e30. doi: 10.1016\/j.urolonc.2013.02.010","journal-title":"Urol Oncol"},{"key":"2640_CR29","unstructured":"Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Zambrano C, Bellmunt J, Burris HA, Teng SM, Shen X, Keoppen H, Hedge PS, Chen DS, Petrylak D (2014) Inhibition of PD-L by MPDL3280A and clinical activity in patients with metastatic urothelial cancer (UBC). J Clin Oncol 32(5s):abstr 5011"},{"issue":"10","key":"2640_CR30","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17(10):3173\u20133181","journal-title":"J Clin Oncol"},{"issue":"11","key":"2640_CR31","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850\u20131855. doi: 10.1200\/JCO.2009.25.4599","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2640-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2640-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2640-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T00:35:28Z","timestamp":1566088528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2640-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2640"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2640-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]}}}